SUN 12:15

Periprocedural management of patients on NOACs: multidisciplinary perspectives

12:15–13:45, Sunday 4 June 2017Room B, PalExpo

Faculty: J Douketis, O Grottke, J Levy, C Pollack and R Whitlock

Join us to discuss the latest developments in periprocedural management of patients on oral anticoagulants, including:

S A T E L L I T E S Y M P O S I U M

• What is the latest guidance on how to prepare patients on NOACs for elective procedures?

• What difference does a NOAC reversal agent make for patients with life-threatening bleeding or requiring urgent surgery?

• What other supportive measures must be undertaken as part of an emergency care strategy?

• What key practical considerations should surgical teams know about NOAC reversal agents?

• Why is multidisciplinary involvement in developing hospital protocols on emergency care management of patients on NOACs essential?

This symposium will encourage audience interaction throughout, allowing you to participate through audience keypad voting and a dedicated question and answer session.

Lunch will be provided

Idarucizumab is approved in the EU, USA, and Japan for reversal of dabigatran anticoagulation in emergency procedures or in uncontrolled/life-threatening bleeding. In Switzerland, idarucizumab is only licenced for dabigatran patients in the bleeding indication.